For example, glutamate-urea-lysine (Glu-urea-Lys), which binds to the prostate-specific membrane antigen (PSMA) with high affinity, was conjugated to PEG-lipids for fabricating targeted LNPs in the treatment of prostate cancer (Lee et al.2016). The gene discussed is FOLH1; the disease is prostate carcinoma.